Therefore, although other neurodegenerative diseases could also affect the levels of Ng both in the brain tissue and the CSF, it could be used in combination with other biomarkers, such as 14-3-3 or tau, also found to be higher in the CSF in preclinical cases of scrapie [8]. The gene discussed is MAPT; the disease is neurodegenerative disease.